Opiate Receptors and Antagonists - nuovo libro

EAN (ISBN-13): 9781588298812
ISBN (ISBN-10): 1588298817
Copertina rigida
Anno di pubblicazione: 2009
Editore: Dean, Reginald, Bilsky, Edward J. Negus, S. Stevens, Humana
519 Pagine
Peso: 1,161 kg
Lingua: eng/Englisch

Libro nella banca dati dal 2008-08-15T01:48:01+02:00 (Zurich)
Pagina di dettaglio ultima modifica in 2023-11-11T10:19:44+01:00 (Zurich)
ISBN/EAN: 1588298817

ISBN - Stili di scrittura alternativi:
1-58829-881-7, 978-1-58829-881-2
Stili di scrittura alternativi e concetti di ricerca simili:
Autore del libro : negus, stevens, dean
Titolo del libro: arthur, opia, reginald, opiate receptors and antagonists from bench clinic

---

Dati dell'editore

Autore: Reginald Dean; Edward J. Bilsky; S. Stevens Negus
Titolo: Contemporary Neuroscience; Opiate Receptors and Antagonists - From Bench to Clinic
Editore: Humana; Humana Press
757 Pagine
Anno di pubblicazione: 2009-03-09
Totowa; NJ; US
Lingua: Inglese
160,49 € (DE)
164,99 € (AT)
177,00 CHF (CH)
Available
XXIII, 757 p.

BB; Hardcover, Softcover / Medizin/Pharmazie; Pharmakologie; Verstehen; Antag; Antagonists; Bench; Clinic; Contemporary; Dean; Ethanol; Neuroscience; Opiate; Opioid; Receptors; marijuana; Pharmacology; BC

Opioid Receptors.- Ultra-Low-Dose Opioid Antagonists Enhance Opioid Analgesia and Reduce Tolerance.- Upregulation of Opioid Receptors.- Imaging Human Brain Opioid Receptors: Applications to Substance Use Disorders.- Opioid Receptor Antagonist-Mediated Signaling in the Immune System.- Opioid Antagonists: Chemistry and Pharmacology.- The Chemistry and Pharmacology of ?-Opioid Antagonists.- Medicinal Chemistry of Kappa Opioid Receptor Antagonists.- The Chemistry and Pharmacology of Delta Opioid Antagonists.- Novel Opioid Antagonists with Mixed/Dual Selectivity.- Experimental Utility and Clinical Potential of Irreversible Opioid Antagonists.- Methylnaltrexone: A Peripherally Acting Opioid Antagonist.- Substance Abuse.- Opioid Antagonist Effects in Animal Models Related to Opioid Abuse: Drug Discrimination and Drug Self-Administration.- Naltrexone for Initiation and Maintenance of Opiate Abstinence.- Ultra-Low-Dose Naltrexone Decreases Dependence and Addictive Properties of Opioids.- Can a Combination Formulation Containing a Neutral Opiate Antagonist Decrease the Abuse of ?-Agonist Opiates.- Effects of Opioid Antagonists on the Abuse-Related Effects of Psychomotor Stimulants and Nicotine.- Potential Use of Opioid Antagonists in the Treatment of Marijuana Abuse and Dependence.- Naltrexone in Smoking Cessation: A Review of the Literature and Future Directions.- Alcohol and Ingestive Behaviors.- Opioid Antagonists and Ethanol's Ability to Reinforce Intake of Alcoholic Beverages: Preclinical Studies.- Clinical Use of Opioid Antagonists in the Treatment of Alcohol Dependence.- Preclinical Effects of Opioid Antagonists on Feeding and Appetite.- CNS Opiate Systems and Eating Disorders.- Behavioral Disorders.- Potential Utility of Kappa Ligands in the Treatment of MoodDisorders.- Opioid Antagonists in the Treatment of Pathological Gambling and Kleptomania.- Efficacy of Opioid Antagonists in Attentuating Self-Injurious Behavior.- Pharmacotherapeutic Effects of Opioid Antagonists in Alcohol-Abusing Patients with Schizophrenia.- Medical Indications.- Current Issues in the Use of Opioid Antagonists (Naltrexone for Opiate Abuse: A Re-Educational Tool as Well as an Effective Drug).- Emergency Room Use of Opioid Antagonists in Drug Intoxication and Overdose.- Kappa-Opioid Antagonists as Pruritogenic Agents.- Clinical Effect of Opioid Antagonists on Clinical Pruritus.- Effects of Opioid Antagonists on l-DOPA-Induced Dyskinesia in Parkinson's Disease.- Endocrine Effects of Opioid Antagonists.- Opioid Antagonists in Traumatic Shock: Animal and Human Studies.- The Efficacy of Opioid Antagonists Against Heatstroke-Induced Ischemia and Injury in Rats.- A Review of the Opioid System in Cancer Patients and Preliminary Results of Opioid Antagonists in the Treatment of Human Neoplasms.- Nonclinical Pharmacology of VIVITROL®: A Monthly Injectable Naltrexone for the Treatment of Alcohol Dependence.- The Development of Sustained-Release Naltrexone and Clinical Use in Treating Opiate Dependence.- The Development of ProNeura Technology for the Treatment of Addictions.- Development of Opioid Transdermal Delivery Systems.- Intranasal Naloxone for Treatment of Opioid Overdose.
Summarizes the present understanding of the chemistry, pharmacology and molecular biology of opioid receptors and their subtypes Highlights differences and similarities between the opioid pharmacology of animals and human Describes current and potential therapeutic areas for opioid antagonists, including substance abuse, alcohol and ingestive behaviors, behavioral disorders and other medical indications, supported by nonclinical and clinical evidence Focuses on the development of exciting and innovative drug delivery approaches that are being used with opioid antagonists for the above medical indications